1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,600 | 12,700 | 16:21 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | BTIG maintains Spyre stock Buy rating, $70 target | 14 | Investing.com | ||
| 27.03. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody | 106 | PR Newswire | Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience... ► Artikel lesen | |
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.03. | Wolfe Research initiates Spyre stock with Outperform rating | 1 | Investing.com | ||
| 27.02. | Spyre Therapeutics GAAP EPS of -$0.81 beats by $0.21 | 2 | Seeking Alpha | ||
| 27.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | 362 | PR Newswire | Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million... ► Artikel lesen | |
| 27.02. | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 27.02. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts | 147 | PR Newswire | Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025
Phase 1 interim results expected for SPY003, an extended... ► Artikel lesen | |
| 13.01. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.12.24 | Spyre begins Phase 1 trials for new IBD treatments | 2 | Investing.com | ||
| 02.12.24 | Spyre startet Phase-1-Studien für neue CED-Behandlungen | 3 | Investing.com Deutsch | ||
| 02.12.24 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies | 255 | PR Newswire | Spyre is concurrently advancing two anti-TL1A molecules into first-in-human studies
Preclinical data for both SPY002 molecules demonstrate picomolar potency and... ► Artikel lesen | |
| 19.11.24 | Spyre Therapeutics announces pricing of $200 million public offering of common stock | 8 | Seeking Alpha | ||
| 19.11.24 | Spyre Therapeutics Prices Public Offering Of About 7.28 Mln Shares At $27.50/shr | - | RTTNews | ||
| 18.11.24 | Spyre Therapeutics startet öffentliches Angebot über 200 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 18.11.24 | Spyre Therapeutics launches $200 million public offering | 1 | Investing.com | ||
| 18.11.24 | Spyre Therapeutics, Inc. - 10-Q/A, Quarterly Report | - | SEC Filings | ||
| 18.11.24 | Spyre Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 18.11.24 | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.24 | Spyre meldet vielversprechende Phase-1-Ergebnisse für IBD-Therapie | 4 | Investing.com Deutsch |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 8,450 | -9,63 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting | Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 23,400 | +5,41 % | Palvella Therapeutics Inc.: Palvella Therapeutics Granted Additional U.S. Patent for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations | Fifth issued patent in the U.S. for QTORIN rapamycin with anticipated patent life extending into 2038 QTORIN rapamycin has the potential to be the first approved therapy and standard of care for microcystic... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 19,700 | +3,68 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results | Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy... ► Artikel lesen | |
| LENZ THERAPEUTICS | 27,030 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights | New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with... ► Artikel lesen | |
| TOURMALINE BIO | 17,820 | -0,39 % | Cantor Fitzgerald maintains Overweight on Tourmaline Bio stock | ||
| EVOTEC | 7,320 | +1,41 % | EQS-News: Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024 | EQS-News: Evotec SE
/ Schlagwort(e): Jahresbericht
Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024
17.04.2025... ► Artikel lesen | |
| TEMPUS AI | 51,04 | +2,97 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
| QIAGEN | 37,535 | -0,03 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| BIONTECH | 102,60 | +1,18 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 13,530 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) | ||
| TARSUS PHARMACEUTICALS | 49,990 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | ||
| NURIX THERAPEUTICS | 11,640 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions | Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical... ► Artikel lesen | |
| CG ONCOLOGY | 20,720 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
| ADMA BIOLOGICS | 22,200 | +2,07 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| BICARA THERAPEUTICS | 15,480 | 0,00 % | Bicara wird aktualisierte Studiendaten auf ASCO-Tagung präsentieren |
Das Unternehmen SPYRE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 12,300 Euro und damit -0,81 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.
